Beinfeld M, Atlas SJ, Touchette D, McKenna A, et al. The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer. J Manag Care Spec Pharm 2021;27:797-804.
PMID: 34057394